The ECF-ITM vaccine is in increasing demand amongst cattle producers in affected regions but it presents numerous technical and practical challenges in its manufacture, registration, storage, transportation and administration. GALVmed’s R&D activities are seeking to alleviate some of these practical constraints through a programme of work that:
There are currently limited disease control options for smallholders facing this major disease of cattle in Africa. In seeking to address this situation, GALVmed is working on three interrelated programmes of work focussing on:
Since 2011, GALVmed has undertaken a substantial programme of work to develop a range of products for this major African livestock disease. Early work included the development of an anti-disease vaccine candidate but this failed to progress beyond exploratory stages of development. The objectives of the current and future programmes of this work are:
Significant GALVmed R&D effort has been focused on this disease with a substantial emphasis on the Clone 13 vaccine. Progress has, however, been limited and a strategic review will be completed in 2015 of current activities and the possible implementation of new approaches. The broad objectives for the period are:
The potential inclusion of RVF within the proposed small ruminant multivalent vaccines.
GALVmed has two small Brucella-related programmes of work with limited objectives. The first relates to the use of antimicrobials for treatment of Brucella in small ruminants and the second to the OIE-stipulated minimum release titre for Brucella vaccines.